The Upcoming PCAC Meeting The FDA notice confirms that the PCAC will convene this summer to evaluate whether to recommend the following seven bulk drug substances for inclusion on the 503A bulks list: July 23, 2026: BPC-157 (free base / acetate) KPV (free base / acetate) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) (free base / acetate) MOTs-C (free base / acetate) July 24, 2026: Emideltide (DSIP) (free base / acetate) Semax (free base / acetate) Epitalon (free base / acetate) All seven substances are of considerable interest to compounding pharmacies, prescribers, and patients
Booking a Vitamin B12 injection is easy
Potential tumor promotion : Given its angiogenic properties, there is theoretical concern it could contribute to tumor growth or neovascularization in certain contexts
We do not offer medical advice, we do not dispense medicines, and we do not promote any product for the diagnosis, treatment, cure, or prevention of any disease or condition in humans or animals
Its peptide vs GLP-1 in action: a natural stimulation of your bodys own fat-burning hormones versus an external hormone (like semaglutide) that alters appetite
